| nicardipine vs trichlormethiazide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.69 [0.29 1.65] | p=1.00 | 0 | 429 | 1 | NICS-EH, | | Cardiovascular death | 4.98 [0.24 104.29] | p=1.00 | 0 | 429 | 1 | NICS-EH, | | stroke (fatal and non fatal) | 0.75 [0.25 2.19] | p=1.00 | 0 | 429 | 1 | NICS-EH, | | Coronary event | 1.00 [0.14 7.13] | p=1.00 | 0 | 429 | 1 | NICS-EH, | | Fatal MI | 1.03 [0.02 52.13] | p=1.00 | 0 | 414 | 1 | NICS-EH, | | Non fatal MI | 1.03 [0.14 7.38] | p=1.00 | 0 | 414 | 1 | NICS-EH, | | Heart failure | 0.14 [0.01 2.77] | p=1.00 | 0 | 429 | 1 | NICS-EH, | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.00 [0.14 7.13] | p=1.00 | 0 | 429 | 1 | NICS-EH, | | Fatal stroke | 7.21 [0.37 140.39] | p=1.00 | 0 | 414 | 1 | NICS-EH, | | Non fatal stroke | 1.03 [0.38 2.80] | p=1.00 | 0 | 414 | 1 | NICS-EH, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
